The FDA approved its first rapid in vitro diagnostic for confirming Ebola virus infections.

The single-use OraQuick Ebola test developed by OraSure Technologies searches for virus antigens in samples to provide an early, probable readout that must later be confirmed with another test. It can be used on human blood—through either venipuncture or finger stick—as well as on oral fluids taken from people suspected to have died from the disease.

 

Credit: CDC Cynthia Goldsmith

Read more…